Publication Name	World Journal of Gastroenterology
Manuscript ID	47542
Country	Greece

Received	2019-03-18 06:28
Peer-Review Started	2019-03-18 12:35
To Make the First Decision	2019-05-14 01:15
Return for Revision	2019-05-15 01:07
Revised	2019-05-20 20:25
Second Decision	2019-06-20 09:11
Accepted by Journal Editor-in-Chief
Accepted by Company Editor-in-Chief	2019-06-26 04:47
Articles in Press	2019-06-26 04:47
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript	2019-07-26 06:55
Publish the Manuscript Online	2019-07-28 10:51

ISSN	1007-9327 (print) and 2219-2840 (online)
Open Access	This article is an open-access article which was selected byan in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Copyright	© The Author(s) 2019 Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Gastroenterology & Hepatology
Manuscript Type	Editorial
Article Title	Role of sodium-glucose co-transporter-2 inhibitors in the management of nonalcoholic fatty liver disease
Manuscript Source	Invited Manuscript
All Author List	Anastasia Kontana and Konstantinos Tziomalos
ORCID	Author(s) ORCID Number Anastasia Kontana http://orcid.org/0000-0003-1226-2078 Konstantinos Tziomalos http://orcid.org/0000-0002-3172-1594
Funding Agency and Grant Number
Corresponding Author	Konstantinos Tziomalos, MD, MSc, PhD, Assistant Professor, First Propedeutic Department of Internal Medicine, Medical School, Aristotle University of Thessaloniki, AHEPA Hospital, 1 Stilponos Kyriakidi Street, Thessaloniki 54636, Greece. ktziomal@auth.gr
Key Words	Nonalcoholic fatty liver disease; Type 2 diabetes mellitus; Sodium-glucose co-transporter-2 inhibitors; Steatosis; Fibrosis; Transaminases
Core Tip	Nonalcoholic fatty liver disease (NAFLD) is more frequent and more severe in patients with type 2 diabetes mellitus (T2DM) than in the general population. Sodium-glucose co-transporter-2 (SGLT2) inhibitors appear to represent a promising option for the management of NAFLD in patients with T2DM. However, existing studies are small, their follow-up period was short and none evaluated the effects of SGLT2 inhibitors on liver histology. Accordingly, larger studies are needed to verify these preliminary results and define the role of SGLT2 inhibitors in the treatment of NAFLD in patients with T2DM.
Publish Date	2019-07-28 10:51
Citation	Kontana A, Tziomalos K. Role of sodium-glucose co-transporter-2 inhibitors in the management of nonalcoholic fatty liver disease. World J Gastroenterol 2019; 25(28): 3664-3668
URL	https://www.wjgnet.com/1007-9327/full/v25/i28/3664.htm
DOI	https://dx.doi.org/10.3748/wjg.v25.i28.3664

Full Article (PDF)	WJG-25-3664.pdf
Manuscript File	47542-Review.doc
Answering Reviewers	47542-Answering reviewers.pdf
Audio Core Tip	47542-Audio core tip.wma
Conflict-of-Interest Disclosure Form	47542-Conflict-of-interest statement.pdf
Copyright License Agreement	47542-Copyright license agreement.pdf
Peer-review Report	47542-Peer-review(s).pdf
Scientific Misconduct Check	47542-Scientific misconduct check.pdf
Scientific Editor Work List	47542-Scientific editor work list.pdf